24-MULTI-65-TB-PMC (TORL123-001): A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

24-MULTI-65-TB-PMC (TORL123-001): A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer Primary: 1. To characterize the safety, tolerability, and DLTs and to determine the MTD and the RP2D of TORL-1-23 administered as monotherapy in participants with advanced cancer 2.To characterize the safety, tolerability, and the RP2D of TORL-1-23 administered in combination with bevacizumab Secondary: 1. To characterize the PK of TORL-1-23 and its breakdown products (MMAE and TORL-1-23MAB) 2. To assess the preliminary antitumor activity of TORL-1-23 in participants with advanced cancer 3. To assess the immunogenicity of TORL-1-23